KIT and neoplasm: The benefit of evaluating metabolic response using [18F]FDG PET/CT is well demonstrated in KIT- or PDGFRA- mutated GIST tumours following treatment with the tyrosine kinase inhibitor; imatinib, [30] as mesenchymal tumours such as GIST rarely demonstrate a reduction in size despite therapeutic response.